Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica J Lin

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
JCO Precision Oncology|May 18, 2022
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific RelapseIbiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2018
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung CancerJessica J Lin, Emily Chin, Beow Y Yeap, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB studyIbiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, et al.
JTO Clinical and Research Reports|September 19, 2022
Clinicopathologic Characteristics and Outcomes for Patients With <i>KRAS</i> G12D-Mutant NSCLCAlissa J Cooper, Alona Muzikansky, Jochen Lennerz, et al.
JTO Clinical and Research Reports|July 11, 2022
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on CrizotinibJaime L Schneider, Alona Muzikansky, Jessica J Lin, et al.
JTO Clinical and Research Reports|August 3, 2023
Efficacy and Tolerability of <i>ALK</i>/<i>MET</i> Combinations in Patients With <i>ALK</i>-Rearranged Lung Cancer With Acquired <i>MET</i> Amplification: A Retrospective AnalysisIbiayi Dagogo-Jack, Lesli A Kiedrowski, Rebecca S Heist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung CancerJessica J Lin, Elizabeth Kennedy, Lecia V Sequist, et al.
Investigational New Drugs|September 17, 2025
Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumorsAlejandro Falcón, Santiago Ponce, Gregory M Cote, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2017
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung CancerJessica J Lin, Lauren L Ritterhouse, Siraj M Ali, et al.
JCO Precision Oncology|January 27, 2022
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung CancersAlexander Drilon, Daniel S W Tan, Ulrik N Lassen, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
JCO Precision Oncology|May 18, 2022
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific RelapseIbiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2018
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung CancerJessica J Lin, Emily Chin, Beow Y Yeap, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB studyIbiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, et al.
JTO Clinical and Research Reports|September 19, 2022
Clinicopathologic Characteristics and Outcomes for Patients With <i>KRAS</i> G12D-Mutant NSCLCAlissa J Cooper, Alona Muzikansky, Jochen Lennerz, et al.
JTO Clinical and Research Reports|July 11, 2022
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on CrizotinibJaime L Schneider, Alona Muzikansky, Jessica J Lin, et al.
JTO Clinical and Research Reports|August 3, 2023
Efficacy and Tolerability of <i>ALK</i>/<i>MET</i> Combinations in Patients With <i>ALK</i>-Rearranged Lung Cancer With Acquired <i>MET</i> Amplification: A Retrospective AnalysisIbiayi Dagogo-Jack, Lesli A Kiedrowski, Rebecca S Heist, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung CancerJessica J Lin, Elizabeth Kennedy, Lecia V Sequist, et al.
Investigational New Drugs|September 17, 2025
Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumorsAlejandro Falcón, Santiago Ponce, Gregory M Cote, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2017
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung CancerJessica J Lin, Lauren L Ritterhouse, Siraj M Ali, et al.
JCO Precision Oncology|January 27, 2022
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung CancersAlexander Drilon, Daniel S W Tan, Ulrik N Lassen, et al.
Pageof 10